Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Marrone

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Journal for Immunotherapy of Cancer|March 8, 2019
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Journal for Immunotherapy of Cancer|February 13, 2019
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
The Lancet. Oncology|July 13, 2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trialDaniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, et al.
Journal for Immunotherapy of Cancer|March 8, 2019
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Journal for Immunotherapy of Cancer|February 13, 2019
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1Kellie N Smith, Nicolas J Llosa, Tricia R Cottrell, et al.
Nature|July 22, 2021
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X Caushi, Jiajia Zhang, Zhicheng Ji, et al.
Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 11